In the phase I/II ARROW, LIBRETTO-001, and LIBRETTO-321 trials assessing selective RET inhibitors in patients with RET fusion-positive NSCLC, a small portion of patients had measurable BrMs at baseline and exhibited intracranial response rates of 56–91% [88,89,90]. The gene discussed is RET; the disease is non-small cell lung carcinoma.